Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Visionstate Announces Deals in Canada and the US, Highlights Growing Opportunities (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tempus AI Inc TEM

Healthcare Biotechnology
Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation... see more

Recent & Breaking News (NDAQ:TEM)

Tempus to Present at 43rd Annual J.P. Morgan Healthcare Conference

Business Wire 14 hours ago

Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions

Business Wire December 18, 2024

New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device

Business Wire December 17, 2024

Personalis and Tempus Expand Collaboration to Biopharma

Business Wire December 16, 2024

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference

Business Wire November 25, 2024

Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®

Business Wire November 12, 2024

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Business Wire November 11, 2024

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 8, 2024

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

Business Wire November 7, 2024

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

Business Wire November 4, 2024

Tempus to Report Third Quarter 2024 Financial Results on November 4

Business Wire November 3, 2024

Tempus to Report Third Quarter 2024 Financial Results on November 7

Business Wire October 24, 2024

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

Business Wire September 26, 2024

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

Business Wire September 12, 2024

Tempus Announces Real World Data Collaboration with BioNTech

Business Wire September 4, 2024

Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Business Wire August 28, 2024

NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

Business Wire August 8, 2024

Tempus Reports Second Quarter 2024 Results

Business Wire August 6, 2024

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

Business Wire August 1, 2024

Tempus Announces Expanded Data and Sequencing Collaboration with Remix Therapeutics

Business Wire July 30, 2024